| Organisation | Type | Fields of acitivity | Focus | based in | Management | Address | Homepage | Profile | Contact | Number of employees | Certificates | BioChancePlus | BioProfile | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NMI Natural and Medical Sciences Institute | Institute | Services | Transfer of research results to industry, Transfer of research findings to the business sector | Reutlingen | Prof. Dr. Hugo Hämmerle (Managing Director) Dr. Alfred Stett (Deputy Managing Director), Prof. Dr. Hugo Hämmerle (Director) Dr. Alfons Stett (Deputy Director) | Markwiesenstr. 55 D-72770 Reutlingen Tel.: +49 (0)7121-515300 Fax: +49 (0)7121-5153016 , Markwiesenstrasse 55 72770 Reutlingen Germany Tel.: +49 (0)7121-515300 Fax: +49 (0)7121-5153016 | info@nmi.de, info@nmi.de | www.nmi.de, www.nmi.de | The NMI was founded in 1985 as a non-profit foundation under civil law. The foundation comprises 12 mostly small- to medium-sized companies as well as the city of Reutlingen. A board of trustees, which is made up of representatives from research and industry, the Ministry of Economic Affairs and the Ministry of Science, Research and the Arts (Baden-Württemberg), oversees the institution. The NMI’s objective is the successful transfer of research findings to the world of business. The NMI covers the following core areas of activity: pharmaceutical and biotechnology research, biomedical technology and surface technology. The scientists who work within the NMI’s 16 research groups are among the pioneers of groundbreaking technologies and are internationally renowned for their innovations and patents. It was here, for example, that micro-electrode arrays (MEAs) were developed. These arrays are used to determine the effects of substances on cardiac muscle and nerve cells. The system was further developed by MCS Multi Channel Systems in Reutlingen and is now marketed worldwide. In conjunction with industrial partners and publicly-funded research institutions, the NMI is also involved in the development of tests based on protein or peptide arrays. In future, these systems will play an important role in diagnostics. By miniaturising and parallelising test systems (microarray technology), numerous parameters can be determined simultaneously in the smallest sample volumes. The use of protein arrays increases the speed of tests and results in a dramatic reduction in the cost of diagnostics, as it is possible to analyse several hundred parameters in a single experiment. Working with other companies, the NMI also initiates projects for the optimisation and further development of implants and surgical instruments. These consortia enable small- and medium-sized companies to take part in research projects under the Institute’s guidance, without having to provide the necessary equipment or scientific expertise themselves. They can access the NMI’s technologies, systems and services, including equipment such as the “Focused Ion Beam”, which enables material samples in the nanometer range to be mapped and prepared. With this latest advancement of the scanning ion microscope, companies from the fields of medical technology and the automotive industry are investigating functional flaws in semiconductor chips, the failure of coatings or instances of corrosion damage. The NMI also operates a comprehensive database (www.biochipnet.com) that is available for biotechnology companies, research institutions and service providers free of charge., NMI was founded in 1985 as a non-profit-making foundation under civil law. The foundation includes 12 mostly small to medium-sized companies and the City of Reutlingen. A board of trustees, which is made up of representatives from research and industry, the Ministry of Economic Affairs and the Ministry of Science and Research (Baden-Württemberg), oversees the institution. The NMI’s objective is to successfully transfer research findings to the world of business. The NMI is an established figure in its core areas of activity, namely: pharmaceuticals and biotechnology, biomedical technology and surface technology. The scientists, who work within the NMI in 13 working groups, are among the pioneers of groundbreaking technologies and are renowned internationally for their innovations and patents. It was here, for example, that micro-electrode arrays (MEAs) were developed. These are used to determine the effects of substances on cardiac muscle and nerve cells. The system was developed further by MCS Multi Channel Systems in Reutlingen and is marketed worldwide. In conjunction with industrial partners and publicly-funded research institutions, the NMI is also involved in the development of tests based on protein or peptide arrays. These systems will in future play an important role in diagnostics. By miniaturising and parallelising testing systems (micro-array technology), a range of measuring parameters can be determined simultaneously in even the smallest sample volumes. The use of protein arrays increases the speed of tests and results in a dramatic reduction in costs for diagnostics, since several hundred measuring parameters can be captured in a single experiment. Working with other companies, NMI also initiates projects for the optimisation and further development of implants and surgical instruments. These consortia enable small and medium-sized companies, under the Institute’s guidance, to take part in research projects without having to come up with the necessary equipment or scientific expertise themselves. They can access the NMI’s technologies, systems and services, such as the “Focused Ion Beam”, which enables material samples in the nanometer range to be mapped and prepared. With this latest further development of the scanning ion microscope, companies from the fields of medical technology and the automotive industry are investigating functional flaws in semiconductor chips, the failure of coatings or instances of corrosion damage. The firm also operates a comprehensive and freely-accessible BioChip database (www.biochipnet.com) for biotechnology companies, research institutions and service providers. | Dr. Nadja Gugeler – Public Relations (gugeler@nmi.de), Dr. Nadja Gugeler - Marketing (gugeler@nmi.de) | ca. 130, Approx. 100 | Postgenomic Screening Platform – modular technology platform for complex biological assays – in conjunction with EDI and accelab GmbH | Joint research project: Bio-reabsorbable collagen fibres for nerve regeneration. Joint research project: Bio-artificial surface substitute for the treatment of degenerative cartilage diseases; subproject 3 | |
| Mediagnost GmbH | Biotech | Development, Medicine, Nutrigenomics, Diagnostics | Testing systems for numerous applications in the field of infection diagnosis, endocrinology and food analysis; the production of antibodies, proteins and viruses | Reutlingen | Dr. Angelika Haage (Managing Director) | Aspenhaustrasse 25 72770 Reutlingen Germany Tel.: +49 (0)7121-51484-0 Fax: +49 (0)7121-51484-10 | info@mediagnost.de | www.mediagnost.de | Mediagnost GmbH was founded in 1985 in Tübingen and is now based in the Tübingen-Reutlingen technology park. Mediagnost produces antibodies, proteins and viruses in accordance with GMT guidelines. The testing systems focus on infectious diseases such as hepatitis A/C, enteroviruses, HIV and the diagnosis of Pseudomonas aeruginosa. The firm’s portfolio also includes testing systems for the qualitative demonstration of genetically-modified foods and contamination of food, along with immunoassays used in endocrinology. | Dr. Angelika Haage | Production in accordance with GLP and GMP guidelines as decreed by the German Drug Law (AMG) and the Act on Medical Devices (MPG). Quality management system certified according to ISO 9001:2000. | AgeQuant – development of a multi-dimensional testing system for the quantitative determination of parameters relevant to regenerative biology in ageing humans. | ||
| Gerwing Medizinprodukte Gerd Riester e.K. | Medtech | Medical Technology | Development, production and distribution of hospital and care supplies. | Jungingen | Gerd Riester (proprietor) | Killertalstrasse 18 72417 Jungingen Germany Phone: +49 (0)7477-1523855 Fax: +49 (0)7477-8036 | info@gerwing-riester.de | www.gerwing-riester.de | GERWING manufactures goods for the hospital wholesale sector. Its product range encompasses almost all aspects of patient fixation in OP surgery, intensive care or hospital beds. In addition, it manufactures universal holders for cannulae (e.g. tracheal cannulae) and tubes. The range of products also includes tourniquets and antidecubitus supports (ankle and elbow pads) made from high-quality Trevira hollow fibre fabric. | Gerd Riester | Gerd Riester |
